Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Angela M.C. Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F. Annabel Niessen, Isabela I. Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina HorváthJennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem Binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J. Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia C.J.L. Bruijning-Verhagen, I-MOVE-COVID-19 hospital study team, VEBIS hospital study team

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.

Originalspråkengelska
Artikelnummer2300187
TidskriftEurosurveillance
Volym28
Nummer47
DOI
StatusPublished - 2023 nov. 23

Bibliografisk information

Publisher Copyright:
© 2023 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Ämnesklassifikation (UKÄ)

  • Infektionsmedicin

Fingeravtryck

Utforska forskningsämnen för ”Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här